NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.52 against a street estimate of -0.66 — a beat of 21.2%.
with an average price target of ₹233.27.
CONFIDENT Strong Q1 FY27 start: 17% revenue growth to ₹2,270cr, EBITDA +72% to ₹285cr with 400bp margin expansion. CDMO +19%, CHG +17%, Consumer +mid-teens. Management reaffirms FY27 guidance; targets 25% EBITDA margins by FY30. Q1 FY27 Overseas facilities have favorable margin profiles (75-85% gross margin) but operate below target scale. India gross margins ~55-65%. Operating leverage expected to drive margin expansion as overseas capacity utilizes. Analysts pressed on growth sustainability (management cautious on repeating Q1 %), capex ROI on new facilities (single-digit millions expected), and overseas breakeven timeline (gradual across jurisdictions, faster in North America). Management deflected specific molecule/customer disclosures to public filings. 2026-07-30…
Full summary in the app.
| Document | Date |
|---|---|
| Investor presentation | 2026-07-29 |
| Annual report FY2026 PIRAMAL PHARMA LIMITED – FINANCIAL YEAR 2025-26 SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹8,869 Crore – Core operating revenue across all | 2026-07-03 |
| Q4 FY26 earnings call | 2026-04-30 |
| Quarterly results · Q4 FY26 PIRAMAL PHARMA LIMITED – DOCUMENT SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • FY2026 Revenue from Operations: Rs 4,782.01 crores (down 9.5% from | 2026-04-28 |
| Investor presentation PIRAMAL PHARMA LIMITED - FINANCIAL SUMMARY FY26 HEADLINE NUMBERS • Revenue from Operations FY26: ₹8,869 Cr (down 3% YoY from ₹9,151 Cr in FY25) • Q4 | 2026-04-28 |
| Q3 FY26 earnings call PIRAMAL PHARMA LIMITED - DOCUMENT SUMMARY DOCUMENT STATUS • This is a regulatory filing notifying stock exchanges about the availability of a confere | 2026-01-30 |
| Quarterly results · Q3 FY26 PIRAMAL PHARMA LIMITED – FINANCIAL RESULTS SUMMARY Quarter & Nine Months Ended December 31, 2025 --- HEADLINE NUMBERS STANDALONE (Core Business) Q | 2026-01-29 |
| Investor presentation PIRAMAL PHARMA LIMITED – Q3 & 9M FY26 RESULTS SUMMARY HEADLINE NUMBERS • 9M FY26 Revenue: ₹6,117 Crores, down 4% YoY from ₹6,397 Crores • Q3 FY26 Re | 2026-01-29 |
Readable in the app.
| Announcement | Date |
|---|---|
| Acquisition of another business or entity announced Piramal Pharma Limited has completed the acquisition of an additional 40.67% stake in Yapan Bio Private Limited for approximately ₹76 crores in cash. This increases Piramal's ownership from | 2026-08-18 |
| Exercise of call option to acquire additional equity stake in Yapan Bio Piramal Pharma Limited has decided to exercise its call option to acquire an additional 41% equity stake in Yapan Bio Private Limited, an associate company. This will increase Piramal's owne | 2026-08-10 |
| Completed acquisition of Kenalog branded commercial injectable product The company has completed the acquisition of Kenalog®, a branded commercial injectable pharmaceutical product. Kenalog® is an established injectable medication in the market, meaning the com | 2026-04-01 |
| Acquisition of Kenalog branded commercial injectable product The company has acquired Kenalog®, a branded commercial injectable pharmaceutical product. This acquisition falls under regulatory disclosure requirements for listed companies on Indian stoc | 2026-01-28 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Piramal Pharma Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.